Evidence map›Paper›PMID 41888884›Full record

ArticleOrphanet journal of rare diseases2026

Targeted therapy for Langerhans cell histiocytosis with maxillofacial involvement in 20 children.

Yang Jiang, Zhigang Li, Ying Yang, Rui Zhang, Tianyou Wang, Guoxia Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yang Jiang *Department of Stomatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health (NCCH), Beijing, 100045, China. BJETYYKQ2016@163.COM.
Zhigang Li *Laboratory of Hematologic Diseases, Hematology Center, Beijing Children's Hospital, Beijing Pediatric Research Institute, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Ying YangLaboratory of Hematologic Diseases, Hematology Center, Beijing Children's Hospital, Beijing Pediatric Research Institute, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Rui ZhangLaboratory of Hematologic Diseases, Hematology Center, Beijing Children's Hospital, Beijing Pediatric Research Institute, Capital Medical University, National Center for Children's Health, Beijing, 100045, China. ruizh1973@126.com.
Tianyou WangLaboratory of Hematologic Diseases, Hematology Center, Beijing Children's Hospital, Beijing Pediatric Research Institute, Capital Medical University, National Center for Children's Health, Beijing, 100045, China. wangtianyou@bch.com.cn.ORCID http://orcid.org/0000-0001-9946-8567
Guoxia YuDepartment of Stomatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health (NCCH), Beijing, 100045, China. yuguoxia@bch.com.cn.

Funding

National Natural Science Foundation of China No.82141119 and No.82070202
6 · The paper itself

Abstract

backgroundTo evaluate targeted therapy for Langerhans cell histiocytosis (LCH) with maxillofacial manifestations, we conducted a retrospective study of 20 children admitted from January 2016 to June 2021.

methodsThe maxillofacial LCH exhibited diverse clinical features and laboratory indices. Seventeen patients were refractory to standard treatments, and three patients directly underwent targeted therapy. Sixteen patients with BRAF

resultsThe cohort included nine males and eleven females, with a median 0.92 years at diagnosis and 1.70 years at initiation of targeted therapy. Three patients had single-system LCH and 17 patients had multi-system LCH. Lesions affected the mandibular bone in 17 patients, the temporal bone in 12 patients, and the maxilla in 10 patients. Ki-67 expression before targeted therapy correlates with maxillary involvement (coefficient 0.61; P < 0.05). The cfBRAF

conclusionOverall, targeted therapy demonstrated good efficacy with mild tolerable adverse events.

Indexed as

Histiocytosis, Langerhans-CellChildChild, PreschoolFemaleHumansImidazolesInfantMaleMAP Kinase Kinase 1MutationOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesRetrospective StudiesBRAF protein, humandabrafenibImidazolesMAP2K1 protein, humanMAP Kinase Kinase 1OximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibBRAF mutationLangerhans cell histiocytosisMAP2K1 mutationMaxillofacial manifestationsTarget therapy

Identifiers

PMID41888884
PMCPMC13023140

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.